Euroopa Liit - eesti - EMA (European Medicines Agency)

resilience biomanufacturing ireland limited - antigeen, mis sisaldab: a / vietnam / 1203/2004 (h5n1), gripivaktsiin (kogu virion, inaktiveeritud) - influenza, human; immunization; disease outbreaks - vaktsiinid - gripi profülaktika ametlikult pandeemia korral. pandeemilise gripi vaktsiini tuleks kasutada vastavalt ametlikele juhistele.

Eesti - eesti - Ravimiamet

bausch + lomb ireland limited - moksifloksatsiin - silmatilgad, lahus - 5mg 1ml 5ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastilised ained - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - tsüstiline fibroos - muud hingamisteede tooted - orkambi tabletid on näidustatud ravi tsüstilise fibroosi (cf) patsientidel vanuses 6 aastat ja vanemad, kes on homozygous jaoks f508del mutatsioon cftr geeni. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Euroopa Liit - eesti - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - tsüstiline fibroos - muud hingamisteede tooted - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Euroopa Liit - eesti - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - tsüstiline fibroos - muud hingamisteede tooted - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Euroopa Liit - eesti - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioödeem, pärilik - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Eesti - eesti - Ravimiamet

mylan ireland limited - sunitiniib - kõvakapsel - 12,5mg 30tk

Eesti - eesti - Ravimiamet

mylan ireland limited - sunitiniib - kõvakapsel - 50mg 28tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - suguhormoonid ja immunoglobuliinid, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.